Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Dr. Natasha Leighl discusses the KRAS G12C space in NSCLC at ITCD2025.
Sotorasib and adagrasib are our approved options but others in development. Will combinations emerge as the best strategy. The heterogeneity within G12C is very striking to me.”
More posts featuring Stephen Liu.
